within Pharmacolibrary.Drugs.ATC.A;

model A01AC54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 5.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Prednisolone is a synthetic glucocorticoid, used for its anti-inflammatory and immunosuppressive properties. In combination products (ATC A01AC54), it is often used as a topical oral anti-inflammatory agent, primarily for conditions affecting the mouth, such as oral ulcers or inflammation. Currently, its topical formulations are approved for short-term management of oral mucosal conditions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical oral administration in general adult population. No specific PK studies for prednisolone, combinations under ATC A01AC54 were found; parameters are based on estimates from systemic administration data adjusted for expected topical exposure.</p><h4>References</h4><ol><li><p>Alfadhel, MM, et al., &amp; Sayed, OM (2023). Numerical Optimization of Prednisolone-Tacrolimus Loaded Ultraflexible Transethosomes for Transdermal Delivery Enhancement; Box-Behnken Design, Evaluation, Optimization, and Pharmacokinetic Study. <i>Gels (Basel, Switzerland)</i> 9(5) –. DOI:<a href=&quot;https://doi.org/10.3390/gels9050400&quot;>10.3390/gels9050400</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37232992/&quot;>https://pubmed.ncbi.nlm.nih.gov/37232992</a></p></li><li><p>Rust, C, &amp; Beuers, U (2005). Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. <i>Clinical reviews in allergy &amp; immunology</i> 28(2) 135–145. DOI:<a href=&quot;https://doi.org/10.1385/CRIAI:28:2:135&quot;>10.1385/CRIAI:28:2:135</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15879619/&quot;>https://pubmed.ncbi.nlm.nih.gov/15879619</a></p></li><li><p>Bodor, ET, et al., &amp; Bodor, N (2016). Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin. <i>Journal of pharmaceutical sciences</i> 105(9) 2873–2878. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2016.03.028&quot;>10.1016/j.xphs.2016.03.028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27179671/&quot;>https://pubmed.ncbi.nlm.nih.gov/27179671</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A01AC54;
